Horizon Therapeutics Public Limited Company  (HZNP)
Other Ticker:  
Price: $116.3000 $0.07 0.060%
Day's High: $116.38 Week Perf: 0.53 %
Day's Low: $ 116.26 30 Day Perf: 0.69 %
Volume (M): 28,881 52 Wk High: $ 116.38
Volume (M$): $ 3,358,884 52 Wk Avg: $107.26
Open: $116.34 52 Wk Low: $90.56

 Market Capitalization (Millions $) 27,207
 Shares Outstanding (Millions) 234
 Employees 1,450
 Revenues (TTM) (Millions $) 3,643
 Net Income (TTM) (Millions $) 438
 Cash Flow (TTM) (Millions $) 572
 Capital Exp. (TTM) (Millions $) 82

Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company is a biopharmaceutical company that focuses on researching, developing, and marketing treatments for rare and rheumatic diseases. The company was founded in 2008 and is headquartered in Dublin, Ireland, with US headquarters in Lake Forest, Illinois.

Horizon Therapeutics has a portfolio of innovative products, with a focus on orphan diseases. The company offers several products that treat rare diseases, including actimmune, which is used to treat chronic granulomatous disease and malignant osteopetrosis, and teprotumumab, a monoclonal antibody used to treat thyroid eye disease. The company also offers several rheumatology products such as KRYSTEXXA, a medication for refractory gout.

Horizon Therapeutics is committed to expanding its capabilities in the rare disease space. The company has a strong pipeline of products in various stages of development, including drugs approved by the FDA for many orphan diseases. The company is focused on the development of innovative treatments for rare diseases where there is a significant unmet need.

Horizon Therapeutics has a global presence, with operations in North America and Europe. The company has collaborations with several pharmaceutical companies to expand its portfolio and develop new drugs. They have agreements with HemoShear Therapeutics, Inc., and River Vision Development Corporation.

Horizon Therapeutics has a strong financial position, with total revenue of $2.4 billion in 2019. The company is committed to creating value for its shareholders, and it has grown exponentially over the years.

In conclusion, Horizon Therapeutics is a biopharmaceutical company committed to improving the lives of people living with rare and rheumatic diseases. With a strong pipeline and collaborations with other pharmaceutical companies, Horizon Therapeutics is well-positioned for continued growth and success into the future.

   Company Address: 70 St. Stephen?s Green Dublin 2 0
   Company Phone Number: 353 1 772 2100   Stock Exchange / Ticker: NASDAQ HZNP
   HZNP is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Horizon Therapeutics Public Limited Company

Horizon Therapeutics Public Limited Company Reports Impressive 7.7% Revenue Growth in April to June 2023, Defying Recent Decline in Stock Performance

Over the past five trading days, the stock of Horizon Therapeutics Public Limited Company experienced a decline of -0.46%. This brings the year to date performance of the stock to -11.95%. Despite this recent decline, the stock is currently trading on the NASDAQ at a 6.8% premium above its 52-week average.
One factor that may have contributed to this decline in stock performance is the company's revenue for the April to June 30, 2023 interval. Revenue during this period increased by 7.712% to $944.00 million, compared to $876.41 million in the same period last year. This growth in revenue is an impressive achievement for the company and indicates a positive trajectory in its financial performance.

Horizon Therapeutics Public Limited Company

Earnings propelled by $35.48 million tax provisions

Horizon Therapeutics Public Limited Company recently reported a return on average invested assets (ROI) of 4.81% in the first quarter of 2023, which is an improvement from its average return on investment of -20.65%. However, this is a decrease from the previous quarter, which can be attributed to the decline in net income.
In comparison to other companies in the Healthcare sector, Horizon Therapeutics Public Limited Company ranks at 1268th with 135 other companies having a higher return on investment. The total ranking has decreased from 517 in the fourth quarter of 2022.
The company's revenue decreased by 6.008% to $832.06 million for the fiscal interval ending on March 31, 2023. This caused earnings to drop by 73.56% to $0.23 in the same quarter compared to $0.87 in the previous year. The company's EPS also declined by 55.56% from the previous quarter, which was $0.52 per share. Revenue deteriorated by 11.674% from $942.03 million.


Horizon Therapeutics Public Limited's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com